Cue Biopharma to Participate in Fireside Chat at The Citizens JMP Life Sciences Conference
Cue Biopharma to Participate in Fireside Chat at The Citizens JMP Life Sciences Conference
BOSTON, May 07, 2024 (GLOBE NEWSWIRE) -- Cue Biopharma, Inc. (Nasdaq: CUE), a clinical-stage biopharmaceutical company developing a novel class of therapeutic biologics to selectively modulate disease-specific T cells, announced today that it will take part in a fireside chat at The Citizens JMP Life Sciences Conference being held in New York, May 13-14, 2024.
波士頓，2024年5月7日（GLOBE NEWSWIRE）——Cue Biopharma, Inc.（納斯達克股票代碼：CUE）是一家處於臨床階段的生物製藥公司，正在開發一種用於選擇性調節疾病特異性T細胞的新型治療生物製劑。該公司今天宣佈，它將參加2024年5月13日至14日在紐約舉行的Citizens JMP生命科學會議的爐邊談話。
During the fireside chat, Cue Biopharma will discuss current oncology and autoimmune disease strategies and progress.
在爐邊談話中，Cue Biopharma將討論當前的腫瘤學和自身免疫性疾病策略和進展。
Presentation Details
演示詳情
The Citizens JMP Life Sciences Conference
Date and Time: Tuesday, May 14 2024, 12:00 – 12:25 p.m. ET
Webcast Link:
Presenter: Daniel Passeri, chief executive officer, Cue Biopharma
Citizens JMP 生命科學會議
日期和時間：美國東部時間 2024 年 5 月 14 日星期二下午 12:00 — 12:25
網絡直播鏈接：
主持人：Cue Biopharma首席執行官丹尼爾·帕塞裏
A live and archived webcast of the fireside chat will be available on the Events page in the Investors and Media section of the Company's website at . The webcast will be archived for 30 days.
公司網站 “投資者與媒體” 部分的 “活動” 頁面上將提供爐邊談話的直播和存檔網絡直播，網址爲。網絡直播將存檔30天。
About Cue Biopharma
Cue Biopharma, a clinical-stage biopharmaceutical company, is developing a novel class of injectable biologics to selectively engage and modulate disease-specific T cells directly within the patient's body. The company's proprietary platform, Immuno-STAT (Selective Targeting and Alteration of T cells) and biologics are designed to harness the curative potential of the body's intrinsic immune system through the selective modulation of disease-specific T cells without the adverse effects of broad systemic immune modulation.
Cue Biopharma
臨床階段的生物製藥公司Cue Biopharma正在開發一類新型的可注射生物製劑，用於直接在患者體內選擇性地參與和調節疾病特異性T細胞。該公司的專有平台Immuno-Stat （選擇性靶向和改變 T 細胞） 生物製劑旨在通過選擇性調節疾病特異性T細胞來利用人體內在免疫系統的治療潛力，而不會受到廣泛的全身免疫調節的不利影響。
Headquartered in Boston, Massachusetts, we are led by an experienced management team and independent Board of Directors with deep expertise in immunology and immuno-oncology as well as the design and clinical development of protein biologics.
我們總部位於馬薩諸塞州波士頓，由經驗豐富的管理團隊和獨立董事會領導，他們在免疫學和免疫腫瘤學以及蛋白生物製劑的設計和臨床開發方面擁有深厚的專業知識。
For more information please visit and follow us on Twitter and LinkedIn.
欲了解更多信息，請在推特和領英上訪問並關注我們。
Investor Contact
Marie Campinell
Senior Director, Corporate Communications
Cue Biopharma, Inc.
mcampinell@cuebio.com
投資者聯繫人
瑪麗·坎皮內爾
企業傳播高級董事
Cue Biopharma, Inc.
mcampinell@cuebio.com
Media Contact
Jonathan Pappas
LifeSci Communications
jpappas@lifescicomms.com
媒體聯繫人
喬納森·帕帕斯
LifeSci
jpappas@lifescicomms.com
譯文內容由第三人軟體翻譯。